NHS
UK researchers warn NHS rollout of Mounjaro could widen inequalities in obesity care
Reported by AI Image generated by AI Fact checked
UK specialists say strict early access rules for the weight-loss drug tirzepatide (Mounjaro) risk creating a “two-tier” obesity treatment system, with people who can pay privately getting faster access than those relying on the National Health Service.
The National Health Service in England will provide a new cream called ruxolitinib for treating non-segmental vitiligo, targeting the immune cells that cause skin pigmentation loss. Clinical trials showed it increased pigmentation in affected areas, offering a more targeted approach than existing options. The decision follows a reassessment by the National Institute for Health and Care Excellence, making it available for those aged 12 and older when other treatments fail.
Reported by AI
A Cl0p ransomware attack has affected patient and staff data at Barts Health NHS. The breach occurred through the organization's Oracle E-Business Suite. Details emerged in a recent report on the incident.